PIP5K1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6502234	0.78	4/20
SCHEMBL6507449	0.76	4/20
SCHEMBL6505419	0.73	4/20
SCHEMBL6503376	0.73	4/20
SCHEMBL6504079	0.70	4/20
SCHEMBL6510087	0.70	4/20
SCHEMBL6506282	0.68	4/20
SCHEMBL6504356	0.68	4/20
SCHEMBL6530015	0.68	4/20
SCHEMBL6506904	0.54	4/20
SCHEMBL6533835	0.46	4/20
SCHEMBL1518720	1.00	3/20
SCHEMBL6501212	1.00	3/20
SCHEMBL6527232	0.92	3/20
SCHEMBL6501419	0.91	3/20
SCHEMBL1519003	0.89	3/20
SCHEMBL6504987	0.88	3/20
SCHEMBL6507989	0.84	3/20
SCHEMBL6500541	0.82	3/20
SCHEMBL6509374	0.80	3/20

Clinical trials — most relevant to PIP5K1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial	PHASE2/PHASE3	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients	PHASE3	COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PIP5K1B binder may also engage these)

Protein	Name	Similarity
P70181	—	1.000	P70181 →
Q5CZZ9	—	1.000	Q5CZZ9 →
D3ZSI8	—	1.000	D3ZSI8 →
PIP5K1A	Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha	1.000	landscape →
Q5ZJ58	—	1.000	Q5ZJ58 →
P70182	—	1.000	P70182 →
O70161	—	1.000	O70161 →
Q9SLG9	—	0.995	Q9SLG9 →
O48709	—	0.994	O48709 →
PIP5K1C	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	0.994	landscape →
Q9M1K2	—	0.994	Q9M1K2 →
Q5I6B8	—	0.993	Q5I6B8 →
Q9M149	—	0.992	Q9M149 →
Q9C813	—	0.992	Q9C813 →
Q9SUI2	—	0.992	Q9SUI2 →
Q9C104	—	0.991	Q9C104 →
Q9LMN1	—	0.991	Q9LMN1 →
Q9W2R3	—	0.991	Q9W2R3 →
Q9HDW4	—	0.991	Q9HDW4 →
Q56YP2	—	0.990	Q56YP2 →
Q9SFB8	—	0.990	Q9SFB8 →
Q22712	—	0.990	Q22712 →
Q9XWP6	—	0.990	Q9XWP6 →
Q8L850	—	0.990	Q8L850 →
F4JX00	—	0.989	F4JX00 →
B3H6Z8	—	0.989	B3H6Z8 →
Q2KHP8	—	0.989	Q2KHP8 →
Q6P158	—	0.989	Q6P158 →
A0A1D9QMS2	—	0.989	A0A1D9QMS2 →
Q5SVQ0	—	0.989	Q5SVQ0 →